LOVELAND, Colo., Dec. 14, 2011 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska"), a leading provider of advanced diagnostic and specialty products to veterinarians, announced today the intent to collaborate with Entegrion Inc., a company with core expertise in blood-related disorders. The parties are to explore unique technologies in the areas of coagulation and blood cell-based therapeutics, for use in the veterinary market.
"Heska is pleased to announce this strategic initiative into an exciting frontier in medicine, and expand our product and service offerings," commented Michael McGinley, President and Chief Operating Officer of Heska. "As part of Heska's stated commitment to growth, focused on the introduction of innovative and competitively differentiated products, we seek to work with innovative leaders in the life science sector. Entegrion is just such an innovator, sharing a parallel path with us in advancing healthcare – Heska committed to advancing animal health, and Entegrion committed to identifying and developing new technologies for human medical needs. We expect this collaboration will lead to the development of products that advance our mutual goals."
Joseph DaCorta, Vice President and Chief Technology Officer for Entegrion Inc., stated "Entegrion is pleased to join forces with Heska, a veterinary industry leader, dedicated to perfecting and supporting quality pet care and whose pursuit of innovation directly matches Entegrion's values and focus on meeting unmet health needs."
Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic and monito